Ra Capital Management, L.P. and 4 Others Buys $46.6M of Bambusa Therapeutics Inc (BBTX) — SEC Form 4, Nov 03, 2026
Reporting Owners
Director
10% Owner
Director
10% Owner
Director
+ 2 more
TXN 2026-11-02
·
FILED 2026-11-03
Equity Position
5.93M sh
-1,495,971 → 5,933,787
Insider Cluster
7 buying
within 30 days — view cluster
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owners
| Name | Relationship |
|---|---|
| Ra Capital Management, L.P. CIK 0001346824 |
Director
10% Owner
|
| Ra Capital Healthcare Fund LP CIK 0001315082 |
Director
10% Owner
|
| Ra Capital Nexus Fund III, L.P. CIK 0001883840 |
Director
|
| Peter Kolchinsky CIK 0001384859 |
Director
10% Owner
|
| Rajeev M. Shah CIK 0001619841 |
Director
10% Owner
|
Ra Capital Management, L.P. at Bambusa Therapeutics Inc
Full insider history
Bought (12 mo)
$46,639,957
Sold (12 mo)
—
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1F2F3 | 2026-10-30 | P - Purchase | 189,909 A | $14.23 | +$2,702,405 | 189,909 | Indirect See footnotes |
| Common StockF4F2F3 | 2026-10-30 | P - Purchase | 263,911 A | $14.92 | +$3,937,552 | 453,820 | Indirect See footnotes |
| Common StockF5F2F3 | 2026-11-02 | C - Conversion | 3,144,858 A | — | 3,598,678 | Indirect See footnotes | |
| Common StockF5F2F6 | 2026-11-02 | C - Conversion | 1,331,080 A | — | 1,331,080 | Indirect See footnotes | |
| Common StockF2F3 | 2026-11-02 | P - Purchase | 2,335,109 A | $16.00 | +$37,361,744 | 5,933,787 | Indirect See footnotes |
| Common StockF2F6 | 2026-11-02 | P - Purchase | 164,891 A | $16.00 | +$2,638,256 | 1,495,971 | Indirect See footnotes |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Series A-1 Preferred StockF5F5F5F2F3 | 2026-11-02 | C - Conversion | 2,844,910 D | $0.00 | 2,844,910 Common Stock | Indirect See footnotes | ||
| Series A-1 Preferred StockF5F5F5F2F6 | 2026-11-02 | C - Conversion | 1,278,148 D | $0.00 | 1,278,148 Common Stock | Indirect See footnotes | ||
| Series A-2 Preferred StockF5F5F5F2F3 | 2026-11-02 | C - Conversion | 299,948 D | $0.00 | 299,948 Common Stock | Indirect See footnotes | ||
| Series A-2 Preferred StockF5F5F5F2F6 | 2026-11-02 | C - Conversion | 52,932 D | $0.00 | 52,932 Common Stock | Indirect See footnotes |
Footnotes (6)
- F1
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.61 to $14.58 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Show more
- F2
- RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Show more
- F3
- Held directly by the Fund. Show more
- F4
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.65 to $15.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Show more
- F5
- All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. Show more
- F6
- Held directly by the Nexus Fund III. Show more
Remarks
Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.
Show moreRelated filings at Bambusa Therapeutics Inc
5%+ Holders · 13D/G
2 filers
-
ATHOS KG 9.2%
Other insiders at Bambusa Therapeutics Inc
GET /v1/forms/4/0001231919-26-001533
API docs
View Original SEC Filing